[HTML][HTML] Somatic copy-number alterations in plasma circulating tumor DNA from advanced EGFR-mutated lung adenocarcinoma patients
A Buder, E Heitzer, J Waldispühl-Geigl, S Weber… - Biomolecules, 2021 - mdpi.com
Background: To assess the clinical relevance of genome-wide somatic copy-number
alterations (SCNAs) in plasma circulating tumor DNA (ctDNA) from advanced epidermal …
alterations (SCNAs) in plasma circulating tumor DNA (ctDNA) from advanced epidermal …
[HTML][HTML] Comparative efficacy of systemic agents for brain metastases from non-small-cell lung cancer with an EGFR mutation/ALK rearrangement: a systematic review …
Background Brain metastases (BM) from non-small-cell lung cancer (NSCLC) are frequent
and carry significant morbidity, and current management options include varying local and …
and carry significant morbidity, and current management options include varying local and …
First-line EGFR TKI therapy in non-small-cell lung cancer: looking back before leaping forward
The sheer impact of epidermal growth factor receptor (EGFR) kinase inhibitors in non-small-
cell lung cancer (NSCLC) cannot be understated. Beyond serving as effective and well …
cell lung cancer (NSCLC) cannot be understated. Beyond serving as effective and well …
[HTML][HTML] Reporting of incidence and outcome of bone metastases in clinical trials enrolling patients with epidermal growth factor receptor mutated lung …
A Brouns, S Dursun, G Bootsma, AMC Dingemans… - Cancers, 2021 - mdpi.com
Simple Summary Around 30–60% of the patients with lung cancer develop bone
metastases, which are associated with decreased survival, bone pain, and skeletal-related …
metastases, which are associated with decreased survival, bone pain, and skeletal-related …
Trilobatin induces apoptosis and attenuates stemness phenotype of acquired gefitinib resistant lung cancer cells via suppression of NF-κB pathway
W Li, X Zihan, W Yizhe, L Yanyang, L Zhixi… - Nutrition and …, 2022 - Taylor & Francis
Trilobatin is a common type of flavonoids compounds derived from Lithocarpus polystachyus
Rehd leaves. Previous report suggests that trilobatin was potentially involved in pro-and …
Rehd leaves. Previous report suggests that trilobatin was potentially involved in pro-and …
Cost-effectiveness analysis of gefitinib plus chemotherapy versus gefitinib alone for advanced non-small-cell lung cancer with EGFR mutations in China
Y Shu, Q Zhang, X He, L Chen - Cancer Management and …, 2021 - Taylor & Francis
Objective The aim of this study was to evaluate the cost-effectiveness of gefitinib plus
chemotherapy (GCP) versus gefitinib alone for advanced non-small-cell lung cancer …
chemotherapy (GCP) versus gefitinib alone for advanced non-small-cell lung cancer …
Chemotherapy and Osimertinib combination should be the first-line treatment for all advanced EGFR+ NSCLC
LN Chen, ATM Lee, M Nagasaka, SHI Ou - Journal of Thoracic Oncology, 2024 - jto.org
Time shapes nearly every aspect of the human experience, dictating how we navigate our
daily lives and the legacies we leave behind. In oncology, patients and clinicians alike are …
daily lives and the legacies we leave behind. In oncology, patients and clinicians alike are …
A novel molecular target in EGFR-mutant lung cancer treated with the combination of osimertinib and pemetrexed
N Takano, M Seike, T Sugano, K Matsuda… - Anticancer …, 2022 - ar.iiarjournals.org
Background/Aim: Synergistic effects of epidermal growth factor receptor tyrosine kinase
inhibitors and chemotherapy have been reported. Here, we evaluated the therapeutic …
inhibitors and chemotherapy have been reported. Here, we evaluated the therapeutic …
Efficacy and Safety of First-Line Therapies in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: A Network Meta-Analysis
K Haeussler, X Wang, KB Winfree, Y D'yachkova… - Future …, 2022 - Taylor & Francis
Aim: To evaluate the comparative efficacy and safety of identified first-line therapies for
patients with EGFR mutation-positive (EGFR m+) advanced non-small-cell lung cancer …
patients with EGFR mutation-positive (EGFR m+) advanced non-small-cell lung cancer …
[HTML][HTML] Progress of targeted and immunotherapy for hepatocellular carcinoma and the application of next-generation sequencing
F Yang, K Deng, H Zheng, Z Liu, Y Zheng - Annals of Hepatology, 2022 - Elsevier
Hepatocellular carcinoma (HCC), leading cancer worldwide, has a high degree of genetic
heterogeneity; next-generation sequencing (NGS) technology has contributed significantly …
heterogeneity; next-generation sequencing (NGS) technology has contributed significantly …